BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

Core Viewpoint - BeyondSpring Inc. is set to present its research on Plinabulin at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting its innovative approach to cancer treatment [1]. Group 1: Company Overview - BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for significant unmet medical needs [3]. - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer (NSCLC) and other indications [3]. - Plinabulin operates through a novel mechanism as a dendritic cell maturation agent, which supports both anti-cancer activity and immune modulation, aiming to enhance tumor sensitivity to checkpoint inhibitors [3]. Group 2: Presentation Details - The poster presentation will take place on April 21, 2026, from 2 PM to 5 PM PT at the San Diego Convention Center [4]. - The session will focus on immunology, specifically under the category of T Cell Engagers 2 / Antibody-Drug Conjugates 1 [4]. - The poster will be numbered 5597 and located at Poster Board Number 16 [4].